Leyman Barbara 4
4 · SUTRO BIOPHARMA, INC. · Filed Aug 26, 2025
Insider Transaction Report
Form 4
Leyman Barbara
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2025-07-08+25,000→ 25,000 total - Tax Payment
Common Stock
2025-07-08$0.78/sh−8,944$6,976→ 16,056 total - Exercise/Conversion
Restricted Stock Units (RSUs)
2025-07-08−25,000→ 75,000 totalExp: 2028-07-08→ Common Stock (25,000 underlying)
Footnotes (3)
- [F1]Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
- [F2]Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
- [F3]The RSUs vest as to 1/4th of the total award annually beginning on July 8, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.